Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
OVAS > SEC Filings for OVAS > Form 8-K on 2-Jul-2013All Recent SEC Filings

Show all filings for OVASCIENCE, INC. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for OVASCIENCE, INC.


2-Jul-2013

Change in Directors or Principal Officers


Item 5.02 (b) and (e): Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 2, 2013, OvaScience, Inc., a Delaware corporation (the "Company") and Scott Chappel, its Chief Scientific Officer, mutually agreed that effective July 31, 2013 (the "Transition Date"), Dr. Chappel will transition from an employee of the Company to a member of the Company's Scientific Advisory Board. As the Company prepares for commercialization next year, Alison Lawton, our Chief Operating Officer, will continue to manage the development and planned launch of the AUGMENT program. Jon Tilly, our scientific co-founder who first discovered egg precursor cells (EggPCs), which form the basis of OvaScience's technology platform, will continue to be extensively involved in the research and development of OvaTure.

In connection with the transition, the Company will pay Dr. Chappel up to four months of base salary, and his options that would have vested during the year after the transition shall continue to do so while he serves on the Scientific Advisory Board.

This Report on Form 8-K includes forward-looking statements about the prospects for the Company's technology in addressing female infertility, the Company's strategy, future plans and prospects, including statements regarding the development and planned launch of the Company's product candidates, including AUGMENT. Any statements in this Report on Form 8-K about our strategy, plans, prospects and future expectations, financial position and operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "aim," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to:
our expectations regarding the regulatory approvals required for AUGMENT; the science underlying our two product candidates (AUGMENT and OvaTure), which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our activities; our dependence on third parties; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to commercialize our product candidates, including AUGMENT, on the timeline we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the "Risk Factors" section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this Report on Form 8-K reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.


  Add OVAS to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for OVAS - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.